Characterization of CTCs in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System

Characterization of CTCs in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System
Conditions:   High Risk Prostate Carcinoma;   Biochemically Recurrent Prostate Carcinoma;   Castration-resistant Prostate Cancer;   Prostate Cancer
Intervention:   Other: Blood collection
Sponsors:   Angle plc;   MidLantic Urology, LLC
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

June 30, 2022Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments